SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial
Key facts
- Where
- Boston, United StatesSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06674109, who can take part
Where in United States
- Massachusetts General HospitalBoston, United StatesContact: Hyon K Choi, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Massachusetts General Hospital
- Trial code
- NCT06674109
- Record updated
- 5 August 2026
- Original description
SAVE-Care (Sodium Glucose Cotransporter-2 inhibitors [SGLT2i] As Novel Gout Care) Trial is a double-blind randomized placebo-controlled trial (RCT) designed to assess the effect of empagliflozin on serum urate [SU] levels of gout patients, as well as levels of highly-sensitivity C-reactive protein [hsCRP] and interleukin 6 [IL-6], and estimate gout flares over 3 months, in order to develop a full-scale RCT of clinical endpoints to directly inform gout care guidelines.Read full original descriptionShow less
SAVE-Care (SGLT2i As Novel Gout Care) Trial
SAVE-Care (Sodium Glucose Cotransporter-2 inhibitors [SGLT2i] As Novel Gout Care) Trial is a double-blind randomized placebo-controlled trial (RCT) designed to assess the effect of empagliflozin on serum urate [SU] levels of gout patients, as well as levels of highly-sensitivity C-reactive protein [hsCRP] and interleukin 6 [IL-6], and estimate gout flares over 3 months, in order to develop a full-scale RCT of clinical endpoints to directly inform gout care guidelines.
Inclusion: In order to be eligible to participate in this study, an individual must meet all of the following criteria:; Provision of signed and dated informed consent form; Fulfilling American College of Rheumatology [ACR]/European Alliance of Associations for Rheumatology [EULAR] gout criteria; 1+ gout flares in last 12 months; Serum urate level ≥ 6mg/dl; Males and females; Age 18-80; Willingness to adhere to the study intervention procedures.
Exclusion: Colchicine or nonsteroidal anti-inflammatory drug [NSAID] prophylaxis; Use of anti-obesity drugs; active cardiovascular disease [CVD], type-1 diabetes; Presence of a condition(s) or diagnosis, either physical or psychological, or physical exam finding that precludes participation. [History of ketoacidosis, end-stage or decompensated liver disease, active cancer]; Estimated Glomerular Filtration Rate [eGFR] <20ml/min; An individual who meets any of the following criteria will be excluded from participation in this study:; pregnant and lactating women; Basal-bolus or multiple daily injection insulin regimens, or loop diuretics.